Rare allele enrichment technology by PCR that enables the selective amplification and detection of low-abundant sequence variants down to 0.01% variant allele frequency (VAF).
NGS-based method that utilizes unique molecular identifiers (UMIs) and highly multiplexed partially nested PCR primer design to detect mutations and copy number variations with high sensitivity.Houston, May 3, 2023 – NuProbe, a genomics company developing ultrasensitive research assays for detecting and monitoring low-frequency mutations, gene…
Read More
Accelerating Precision Oncology Worldwide
Clinical and Research Laboratories
At NuProbe, we are developing innovative assays to accelerate cancer research. Our products allow laboratories to detect and quantify low-abundant variants across multiple platforms from both cell-free DNA and tissue specimens. Contact us today to learn more.
Pharma
We provide assay development and testing services to support all stages of biomarker detection programs. Our flexible platform utilizes proprietary technologies to deliver best-in-class sensitivity from solid tumor and liquid biopsy. Contact one of our experts today to find out what NuProbe can do for you.
Never miss an update
Stay in touch for the latest NuProbe developments
Upcoming Events
JUN 2-6, 2023
ASCO Annual Meeting
